Latest Novocure News & Updates

See the latest news and media coverage for Novocure. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Novocure

Oncology medical device company

novocure.com
Headquarters
Baar, Switzerland
Founded year
2000
Company type
Public company
Number of employees
1,400–5,000

Last updated

Latest news about Novocure

In short: Novocure achieved 12% revenue growth in Q1 2026, driven by the FDA approval and launch of its Optune Pax treatment for pancreatic cancer.

Company announcements

  • Novocure

    Novocure reports Q1 2026 financial results

    Net revenues reach $174 million, up 12% year-over-year. Optune Pax gains FDA approval and launches for pancreatic cancer. Active patients total 4,791 globally.

  • Novocure

    Novocure reports Q1 2026 financial results on April 30

    Details are available in the press release.

  • Novocure

    Novocure announces positive topline results from PANOVA-4 trial

    The Phase 2 trial met its primary endpoint with 74.4% disease control rate in metastatic pancreatic cancer patients treated with TTFields plus chemotherapy, exceeding historical control. Novocure plans future presentations.

  • Novocure

    Novocure announces Optune Lua reimbursement approval in Japan

    Japan’s Ministry of Health approves national health insurance coverage for Optune Lua in treating advanced NSCLC with PD-1/PD-L1 inhibitors.

Unlock all announcements with a

Media coverage

Unlock all articles with a

Never miss news about Novocure

Track Novocure and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.